ES2091689T3 - Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. - Google Patents

Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.

Info

Publication number
ES2091689T3
ES2091689T3 ES94903936T ES94903936T ES2091689T3 ES 2091689 T3 ES2091689 T3 ES 2091689T3 ES 94903936 T ES94903936 T ES 94903936T ES 94903936 T ES94903936 T ES 94903936T ES 2091689 T3 ES2091689 T3 ES 2091689T3
Authority
ES
Spain
Prior art keywords
treatment
application
pct
oxcarbazepine
carbamazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903936T
Other languages
English (en)
Inventor
Alain Boireau
Adam Doble
Pierre Dubedat
Erik Louvel
Mireille Meunier
Jean-Marie Miquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2091689T3 publication Critical patent/ES2091689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

APLICACION DE UN ANTICONVUSIONANTE ELEGIDO ENTRE LA CARBAMACEPINA O LA OXCARBACEPINA O LAS SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS DESTINADOS AL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON Y DE LOS SINDROMES PARKINSONIANOS.
ES94903936T 1993-01-07 1994-01-03 Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. Expired - Lifetime ES2091689T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300074A FR2700117B1 (fr) 1993-01-07 1993-01-07 Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Publications (1)

Publication Number Publication Date
ES2091689T3 true ES2091689T3 (es) 1996-11-01

Family

ID=9442862

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94903936T Expired - Lifetime ES2091689T3 (es) 1993-01-07 1994-01-03 Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
ES94903935T Expired - Lifetime ES2092890T3 (es) 1993-01-07 1994-01-03 Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94903935T Expired - Lifetime ES2092890T3 (es) 1993-01-07 1994-01-03 Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.

Country Status (23)

Country Link
US (2) US5674885A (es)
EP (2) EP0678026B1 (es)
JP (2) JP3120153B2 (es)
KR (2) KR100298807B1 (es)
AT (2) ATE144420T1 (es)
AU (3) AU677279B2 (es)
CA (2) CA2153341A1 (es)
CZ (2) CZ284363B6 (es)
DE (2) DE69400799T2 (es)
DK (2) DK0678026T3 (es)
ES (2) ES2091689T3 (es)
FR (1) FR2700117B1 (es)
GR (2) GR3020975T3 (es)
HU (2) HU217136B (es)
IL (3) IL108286A0 (es)
MX (2) MX9307885A (es)
NO (2) NO307495B1 (es)
PL (2) PL309594A1 (es)
RU (1) RU2221563C2 (es)
SK (2) SK279758B6 (es)
UA (1) UA29464C2 (es)
WO (3) WO1994015607A1 (es)
ZA (3) ZA9428B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
EP1043996A2 (en) * 1998-01-09 2000-10-18 Mor-Research Applications Ltd. Treatment of dyskinesias
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
ES2211373T1 (es) * 2001-02-12 2004-07-16 Teva Pharmaceutical Industries Ltd. Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
EP1924326B1 (en) 2005-08-25 2016-10-12 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
US20070178164A1 (en) * 2006-01-31 2007-08-02 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
CA2699411A1 (en) * 2007-09-14 2009-03-19 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
MX353752B (es) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CA3027300C (en) 2016-06-13 2023-08-08 Syneurx International (Taiwan) Corp. Co-crystals of lithium benzoate and uses thereof
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
EP3638283B1 (en) * 2017-06-14 2024-07-17 Lario Therapeutics Ltd. Antagonists of cav2.3 r-type calcium channels for the treatment of neurodegenerative diseases
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
EP4031135A4 (en) 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
EP4780448A1 (en) * 2023-09-18 2026-07-29 Aribio Co., Ltd. Lamotrigine and rivastigmine combinations for treating neurodegenerative disorders
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
FR2619713B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Also Published As

Publication number Publication date
CA2153340C (fr) 2002-12-17
JP3120153B2 (ja) 2000-12-25
CZ176495A3 (en) 1995-12-13
US5658900A (en) 1997-08-19
DK0678026T3 (da) 1996-09-16
SK279645B6 (sk) 1999-01-11
GR3021438T3 (en) 1997-01-31
CA2153341A1 (fr) 1994-07-21
IL108284A (en) 1999-03-12
KR960700059A (ko) 1996-01-19
CA2153340A1 (fr) 1994-07-21
ZA9426B (en) 1994-08-11
JPH08505379A (ja) 1996-06-11
NO952309L (no) 1995-06-12
ZA9432B (en) 1994-08-11
CZ284928B6 (cs) 1999-04-14
HUT72328A (en) 1996-04-29
NO952309D0 (no) 1995-06-12
WO1994015610A1 (fr) 1994-07-21
AU5818994A (en) 1994-08-15
RU2221563C2 (ru) 2004-01-20
EP0678026A1 (fr) 1995-10-25
DE69400435D1 (de) 1996-10-02
WO1994015607A1 (fr) 1994-07-21
IL108286A0 (en) 1994-04-12
SK86795A3 (en) 1995-11-08
EP0678023B1 (fr) 1996-10-23
EP0678026B1 (fr) 1996-08-28
DK0678023T3 (da) 1996-11-25
AU5818894A (en) 1994-08-15
ATE141792T1 (de) 1996-09-15
DE69400799T2 (de) 1997-03-13
JPH08505378A (ja) 1996-06-11
PL309596A1 (en) 1995-10-30
MX9400287A (es) 1994-07-29
CZ176595A3 (en) 1995-12-13
HU217136B (hu) 1999-11-29
ATE144420T1 (de) 1996-11-15
MX9307885A (es) 1994-07-29
NO952310L (no) 1995-06-12
FR2700117B1 (fr) 1995-02-03
AU677279B2 (en) 1997-04-17
ZA9428B (en) 1994-08-11
PL309594A1 (en) 1995-10-30
SK86695A3 (en) 1996-05-08
CZ284363B6 (cs) 1998-11-11
FR2700117A1 (fr) 1994-07-08
NO952310D0 (no) 1995-06-12
KR960700054A (ko) 1996-01-19
SK279758B6 (sk) 1999-03-12
IL108285A0 (en) 1994-04-12
EP0678023A1 (fr) 1995-10-25
HU9502065D0 (en) 1995-09-28
GR3020975T3 (en) 1996-12-31
ES2092890T3 (es) 1996-12-01
WO1994015601A1 (fr) 1994-07-21
US5674885A (en) 1997-10-07
HUT72074A (en) 1996-03-28
DE69400435T2 (de) 1997-03-06
DE69400799D1 (de) 1996-11-28
HU9502063D0 (en) 1995-09-28
NO307495B1 (no) 2000-04-17
KR100298807B1 (ko) 2001-11-22
IL108284A0 (en) 1994-04-12
UA29464C2 (uk) 2000-11-15
AU5819094A (en) 1994-08-15
AU684059B2 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
AU677279B2 (en) Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes
MX9307884A (es) Aplicacion de la carbamazepina o la oxcarbamazepina para la preparacion de medicamentos para el tratamiento de lesiones neurologicas ligadas a traumatismos.
NO307204B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter ved behandling av stråleskader

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19960401

FG2A Definitive protection

Ref document number: 678026

Country of ref document: ES